IndustryCompany release

CorMedix posts $54.5M Q3 revenue, narrows 2026 EBITDA guidance and details Heron asset deal

🇺🇸 CorMedix Inc. (CRMD) · Mon 16 Nov 2026

On its 12 November earnings call, CorMedix also discussed the CMS 2027 ESRD final rule for DefenCath and the FDA's priority review of a REZZAYO sNDA.

CorMedix reported third-quarter revenue of $54.5M and cash of $355M on its earnings call on 12 November 2026. The company narrowed its full-year 2026 adjusted EBITDA guidance to a range of $130M to $140M.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): CorMedix Inc. ↗

Article written by VigiEye from the official source (CorMedix Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →